| Active substance | Ribociclib |
| Holder | Novartis Pharma |
| Status | closed |
| Indication | The adjuvant treatment of patients with ribociclib diagnosed with early-stage Hormone Receptor-positive (HR+), Human Epidermal growth factor Receptor 2-negative (HER2─) breast cancer (stages II and III) requiring adjuvant treatment with an endocrine treatment based regimen. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 02/07/2025 |